

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)



(10) International Publication Number
WO 2021/161287 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/IB2021/051267

(22) International Filing Date:
15 February 2021 (15.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/977,292 16 February 2020 (16.02.2020) US
63/139,315 20 January 2021 (20.01.2021) US

(71) Applicant: **AULOS BIOSCIENCE, INC** [US/US]; 245
Main Street, 12th Floor, Cambridge, Massachusetts 02142
(US).

(72) Inventors: **AMIT, Inbar**; Emek Ayalon 23, 7174512
Modiin (IL). **LEVIN, Itay**; Brenner 37, 4642758 Herzeliya
(IL). **NIMROD, Guy**; 54 Pinkas St, Apt 48, 6226118 Tel
Aviv (IL). **FISCHMAN, Sharon**; Miriam HaHashmonait
St 18, 7176237 Modi'in (IL). **BARAK FUCHS, Reut**; Prof.
Aaron Ciechanover 7, 7608625 Rehovot (IL). **ŠTRAJBL,
Marek**; Nikanor 35, 9330746 Jerusalem (IL). **WYANT,
Timothy**; 6 Maddie Way, Bellingham, Massachusetts
02019 (US). **ZHENIN, Michael**; 3 HaHartsit Str, Apt 15,
9658603 Jerusalem (IL). **BLUVSHTEIN YERMOLAEV,
Olga**; Harav Neria 6/19, 7575120 Rishon-LeZion (IL).
SASSON, Yehezkel; Hailanot 10, 4486200 Tzur Yigal (IL).
GROSSMAN, Noam; Yigal Alon 1, 7685201 Mazkeret
Batya (IL). **LEVITIN, Natalia**; Nahal Snir 17/12, 7771717
Ashdod (IL). **OFRAN, Yanay**; 21 Akiva Arie St, 6215421
Tel Aviv (IL).

(74) Agent: **COHEN, Mark S.** et al.; Pearl Cohen Zedek Latzer
Baratz LLP, 7 Times Square, 19th Floor, New York, New
York 10036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: ENGINEERED ANTI-IL-2 ANTIBODIES

(57) Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.

WO 2021/161287 A2